EFM
ALLO icon

E Fund Management’s Allogene Therapeutics ALLO Stock Holding History

E Fund Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99K Buy
47,593
+12,101
+34% +$26.6K ﹤0.01% 474
2026
Q1 		$86.6K Buy
+35,492
New +$71.1K ﹤0.01% 476
2025
Q1 		– Sell
-25,992
Closed -$55.4K – 400
2024
Q4 		$55.4K Buy
25,992
+5,629
+28% +$13.9K ﹤0.01% 387
2024
Q3 		$57K Sell
20,363
-4,970
-20% -$13.2K ﹤0.01% 349
2024
Q2 		$59K Sell
25,333
-11,797
-32% -$34.8K ﹤0.01% 314
2024
Q1 		$166K Buy
+37,130
New +$155K 0.01% 356
2023
Q4 		– Sell
-40,325
Closed -$128K – 309
2023
Q3 		$128K Sell
40,325
-736
-2% -$3.23K 0.01% 274
2023
Q2 		$204K Buy
41,061
+2,624
+7% +$14.2K 0.02% 277
2023
Q1 		$190K Sell
38,437
-1,208
-3% -$7.75K 0.01% 305
2022
Q4 		$249K Buy
39,645
+8,037
+25% +$74.4K 0.02% 260
2022
Q3 		$341K Buy
31,608
+6,602
+26% +$89.7K 0.03% 215
2022
Q2 		$285K Sell
25,006
-3,309
-12% -$29.4K 0.03% 242
2022
Q1 		$258K Buy
+28,315
New +$295K 0.01% 248

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

E Fund Management's ALLO Position: Q2 2026 in Review

E Fund Management increased its Allogene Therapeutics (ALLO) stake by 34% in Q2 2026, buying an estimated $26.6K and bringing the position to 47,593 shares worth $99K. The position accounts for ﹤0.01% of the portfolio, ranked #474.

E Fund Management first reported a position in ALLO in Q1 2022 and has held it in 13 quarters since. The position peaked at $341K in Q3 2022. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • E Fund Management held 47,593 shares of Allogene Therapeutics worth $99K as of Q2 2026.
  • E Fund Management bought 12,101 Allogene Therapeutics shares in Q2 2026, an estimated $26.6K.
  • Allogene Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #474 holding.
  • E Fund Management first reported a position in Allogene Therapeutics in Q1 2022 and has held it in 13 quarters since.
  • E Fund Management's Allogene Therapeutics position peaked at $341K in Q3 2022.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.